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Abstract The N-acylphosphatidylethanolamine-hydrolysing
phospholipase D (NAPE-PLD) generates N-acylethanolamines,
including N-arachidonoyl-ethanolamine (anandamide), that may
be neuroprotective and analgesic. The properties of NAPE-PLD
from rat heart and brain microsomes are investigated and
compared to those of other PLDs. NAPE-PLD is inhibited by
the fatty acid aminohydrolase inhibitor MAFP in high concen-
trations (v100 WM) while PMSF in high concentrations (10
mM) tends to stabilise NAPE-PLD activity. Oleate inhibits
NAPE-PLD but the enzyme is not affected by PIP2, K-synuclein
or mastoparan. Furthermore, it is for the first time reported that
NAPE-PLD is not capable of catalysing a transphosphatidyla-
tion reaction like most other known PLDs.
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1. Introduction
Phospholipase D (PLD) enzymes are widely distributed in
mammalian cells, where some of them are regulated by a
variety of hormones, growth factors, and other extracellular
signals [1]. The phosphatidylcholine-speci¢c PLDs have been
widely investigated. Both the human PLD1 [2] and PLD2 [3]
have recently been cloned. The major substrate phosphatidyl-
choline (PC) is hydrolysed by these PLDs as well as by an
oleate-dependent PLD [4] to phosphatidic acid (PA) and cho-
line. These PLDs are identi¢ed and quanti¢ed in cells and
tissues by their ability to catalyse a transphosphatidylation
reaction in the presence of a primary alcohol, producing phos-
phatidylalcohol instead of phosphatidic acid [5^7].
N-acylphosphatidylethanolamine (NAPE) is hydrolysed by
a PLD subtype (NAPE-PLD) to PA and N-acylethanolamine
(NAE) [8,9]. NAPE is only present in very small amounts in
mammalian tissue. A signi¢cant increase in the formation of
NAPE and NAE, including N-arachidonoyl-ethanolamine
(anandamide), is seen when neurones are exposed to a neuro-
toxic environment [10^12]. It has been suggested that NAPE
and NAE may serve a cytoprotective role as a response to the
high intracellular calcium concentrations that are seen in in-
jured cells [13].
Anandamide has been proposed to have a physiological role
as an endogenous ligand for the cannabinoid receptor CB1
[14,15]. It has recently been shown that cannabinoid receptor
agonists can protect neurones against excessive NMDA recep-
tor stimulation via presynaptic CB1 receptor-mediated inhi-
bition of glutamate release [16]. N-palmitoyl-ethanolamine
(PEA) can also be formed by NAPE-PLD-catalysed hydroly-
sis and may act on CB2-like receptors [17,18].
NAPE-PLD may play an important role for the formation
of anandamide, PEA as well as other NAEs, e.g. in terms of
protecting neurones against excitotoxicity and peripheral in
the formation of local analgesics [18]. Mammalian NAPE-
PLD has previously been preliminary characterised [19]. How-
ever, it has not been known whether this NAPE-PLD can
transphosphatidylate or whether it resembles the other known
mammalian PLDs in terms of inhibitors and activators.
2. Materials and methods
2.1. Materials
1-Palmitoyl-2-[1P-14C]linoleoyl-sn-glycero-3-phosphoethanolamine
(56 mCi/mmol) and [1-14C]palmitic acid (55 mCi/mmol) were from
Amersham Pharmacia Biotech (Amersham, UK). Phosphatidyletha-
nol was from Avanti Polar Lipids (Alabaster, AL, USA). Methyl
arachidonyl £uorophosphonate (MAFP) and phoshatidylbutanol
were from Biomol (Plymouth Meeting, MA, USA). Synthetic masto-
paran from Vespula lewisii and PLD from Streptomyces species (St.
sp.) were from Sigma Chemical Co. (St. Louis, MO, USA). Karina
Petersen, Lundbeck A/S (Valby, Denmark) kindly provided puri¢ed
recombinant human K-synuclein.
2.2. Synthesis of N-acylphosphatidylethanolamines
1-Palmitoyl-2-oleoyl-sn-glycero-3-phospho(N-[1P-14C]palmitoyl) eth-
anolamine and 1,2-dilauroyl-sn-glycero-3-phospho- (N-[1P-14C]-palmit-
oyl)ethanolamine were prepared essentially as described by Schmid et
al. [19] with a speci¢c activity of 5000 dpm/nmol. 1-Palmitoyl-2-
[1P-14C]linoleoyl-sn-glycero-3-phospho(N-oleoyl)ethanolamine was
synthesised according to Shangguan et al. [20] with a speci¢c activity
of 500 dpm/nmol. The products were puri¢ed by thin-layer chroma-
tography (TLC) and developed in chloroform: methanol:ammonium
hydroxide (80:20:2 v/v/v).
2.3. Subcellular fractionation
Hearts and brains from 13^17 weeks old Sprague-Dawley rats were
homogenised with an UltraTurrax in 10 v/w 25 mM Tris-HCl bu¡er,
0.25 M sucrose, 2 mM EDTA, pH 7.3. Microsomal fractions were
prepared from the 1000Ug supernatant by centrifugation at
109 000Ug. The resultant pellet (microsomes) was resuspended in
60 mM bis-Tris propane, 2 mM 1,4-dithiothreitol, pH 8.0 at a con-
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centration of 3^19 mg of protein/ml. Protein was determined by the
method of Bradford [21].
2.4. Assay of PLD activity
The substrate (NAPE) was dried under a stream of nitrogen, resus-
pended in 60 mM bis-Tris propane, 2 mM 1,4-dithiothreitol, pH 8.0
and sonicated for 10 min. 200 Wg of protein from rat heart or rat
brain microsomes was added to a ¢nal volume of 200 Wl. Incubations
were carried out at 37‡C. When indicated the incubation mixture also
consisted of Triton X-100, phenylmethylsulfonyl£uoride (PMSF) and
dimethylsulfoxide (DMSO). The reactions were terminated by adding
1.5 ml of ice-cold chloroform:methanol (2:1 v/v) and the lipids were
extracted. Separation of the lipids was carried out by TLC, developing
the plates in chloroform:methanol:ammonium hydroxide (80:20:2
v/v/v). After development, the reaction products were located and
quanti¢ed by a PhosphoImager scanner (STORM, Molecular Dynam-
ics, Sunnyvale, CA, USA).
3. Results and discussion
3.1. Time-dependent NAE formation
The amount of NAE (PEA) formed under the standard
assay conditions including 0.6 mM Triton X-100, 10 mM
PMSF and 5 Wl DMSO was linear for at least 8 h of incuba-
tion at 37‡C. PEA was formed at a rate of 700 pmol per h per
mg protein using rat heart microsomes while incubations with
rat brain microsomes resulted in the lower rate of 520 pmol
PEA per h per mg protein (data not shown).
3.2. E¡ects of FAAH inhibitors on NAPE-PLD activity
In order to avoid hydrolysis of NAE during the NAPE-
PLD assay two di¡erent fatty acid aminohydrolase (FAAH)
inhibitors were investigated. MAFP has recently been re-
ported to be a very potent irreversible FAAH inhibitor
[22,23]. Fig. 1A shows that 1 WM MAFP increases PEA for-
mation due to inhibition of FAAH activity. Complete inhibi-
tion of FAAH has earlier been reported by Schmid et al. [24]
to occur at similar concentrations, i.e. 0.1^1 WM MAFP de-
pendent on the dilution of the membrane preparation. NAPE-
PLD activity is signi¢cantly inhibited adding 100 times higher
concentration of MAFP (Fig. 1B). It is therefore concluded
that it is safe to use 1 WM MAFP in the NAPE-PLD assay.
Fig. 1. E¡ect of increasing concentrations of MAFP on NAPE-PLD
activity and FAAH activity. 10 WM 1-palmitoyl-2-oleoyl-sn-glycero-
3-phospho(N-[1P-14C]palmitoyl)ethanolamine was incubated for 3 h
under the described conditions, various concentrations of MAFP
added in 2 Wl of DMSO and protein from rat brain microsomes.
A: The relative activity of NAPE-PLD-catalysed PEA (8) forma-
tion and FAAH-catalysed palmitic acid (F) formation. B: NAPE-
PLD activity calculated as the sum of PEA and palmitic acid for-
mation. 100% activity in A equals 127 pmol PEA/h/mg protein and
77 pmol palmitic acid/h/mg protein, respectively. Data represent
means þ S.E.M. of one experiment performed in duplicate. Another
experiment with concentrations of MAFP up to 100 WM showed the
same inhibition as the above data.
Fig. 2. E¡ect of increasing concentrations of PMSF on NAPE-PLD
activity and FAAH activity. 10 WM 1-palmitoyl-2-oleoyl-sn-glycero-
3-phospho(N-[1P-14C]palmitoyl)ethanolamine was incubated for 3 h
under the described conditions, various concentrations of PMSF
added in 2 Wl of DMSO and protein from rat brain microsomes.
A: The relative activity of NAPE-PLD-catalysed PEA (8) forma-
tion and FAAH-catalysed palmitic acid (F) formation. B: NAPE-
PLD activity calculated as the sum of PEA and palmitic acid for-
mation. 100% activity in A equals 127 pmol PEA/h/mg protein and
77 pmol palmitic acid/h/mg protein, respectively. Data represent
means þ S.E.M. of one experiment performed in duplicate. Another
experiment was carried out with PMSF added in 10 Wl of DMSO
with the same results.
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PMSF, which has been known to inhibit serine proteases
and some thiol proteases, was in 1993 also reported to abolish
FAAH activity [25]. Fig. 2A shows that 0.1 mM PMSF e¡ec-
tively inhibits FAAH activity and thereby increases PEA for-
mation. These results imply that MAFP is 100 times more
potent than PMSF in inhibiting FAAH. This is in good agree-
ment with results obtained by Deutsch et al. [22]. Higher
concentrations of PMSF tend to increase NAPE-PLD activity
(Fig. 2B).
The potentiating e¡ect of PMSF on NAPE-PLD activity
was studied in more detail. An experiment was carried out
pre-incubating the microsomes 1^8 h at 37‡C with PMSF
and without substrate. The results showed a signi¢cant de-
crease of 40% in NAPE-PLD activity in rat brain microsomes
after 1 h of pre-incubation while only 13% decrease in NAPE-
PLD activity was seen in rat heart microsomes after 8 h of
pre-incubation (data not shown). These results suggest that
the potentiating e¡ect of PMSF is conducted via prevention
of NAPE-PLD degradation due to inhibition of proteases by
PMSF.
3.3. Detergent e¡ects of Triton X-100
Triton X-100 has earlier been reported to be the only de-
tergent stimulating NAPE-PLD activity in in vitro assays. The
optimum NAPE-PLD activity was found to be 2.0 mg/ml
Triton X-100 in rat brain microsomes [19] and 4 mM Triton
X-100 in dog brain microsomes [26]. 0.6 mM Triton X-100
was here found to be the optimal concentration of detergent
while a 10-fold increase in concentration of the detergent re-
sulted in 69% inhibition of NAPE-PLD activity (data not
shown).
3.4. NAPE-PLD exposed to known activators/inhibitors of
PLD activity
It has been suggested that PLD1 and PLD2 act through
similar catalytic mechanisms since both enzymes have an ab-
solute requirement for phosphatidylinositol 4,5-bisphosphate
(PIP2) for activation [3]. Experiments performed using rat
heart microsomes showed that mammalian NAPE-PLD activ-
ity is not stimulated by PIP2, neither when PIP2 is included in
lipid vesicles in 0.1, 1 or 10 mol% with PC (Fig. 3) or PE (data
not shown). The decrease in NAPE-PLD activity seen when
9-fold phospholipid was added can most likely be ascribed to
a non-speci¢c surface dilution of the substrate [27] since the
same decrease was seen whether PC or PE was added. Addi-
tion of PA or PS seems to inhibit NAPE-PLD activity while
PI stimulates the enzyme.
K-Synuclein and L-synuclein proteins have been reported to
selectively inhibit mammalian PLD2 [28]. It was suggested
that PLD2 might be involved in synaptic vesicle cycling and
that the synucleins are important regulatory components of
this process. Jenco et al. [28] showed that 100 nM of K-syn-
uclein inhibited PLD2 completely. No inhibitory e¡ect was
seen when 0.1^400 nM human recombinant K-synuclein was
tested on NAPE-PLD activity using rat brain microsomes
(data not shown).
Mammalian tissues also contain PLD activities that can be
stimulated by unsaturated fatty acids such as oleate, linoleate,
linoleneate and arachidonate (oleate-dependent PLD)
[4,29,30]. The most e¡ective in vitro activator concentrations
were found to be around 4 mM [31]. In contrast, rat heart
NAPE-PLD activity was inhibited by oleate (Fig. 3), as are
PLD1 and PLD2 enzymes [2,32].
Mastoparans exhibit a wide variety of biological e¡ects,
including a¡ecting the activity of PLA2 and PLC, see [33].
Stimulation of PLD activity has been reported in carnation
petals [34] as well as in L1210 cells [35]. Fensome et al. [36]
have on the contrary observed that GTPQS-stimulated PLC-L
and PLD activity were inhibited by mastoparan. All these
mechanisms have been related to the activation of G-proteins
[37,38] or induction of membrane perturbation [33]. 25 WM
mastoparan has been reported to stimulate NAPE-PLD activ-
Fig. 3. E¡ect of phospholipids and oleate on NAPE-PLD activ-
ity. 10 WM 1,2-dilauroyl-sn-glycero-3-phospho(N-[1P-14C]palmitoyl)-
ethanolamine was incubated for 30 min under the described condi-
tions, including 0.6 mM Triton X-100, 10 mM PMSF, 5 Wl DMSO
and protein from rat heart microsomes. Data represent means
þ S.E.M. of one experiment performed in duplicate. A second ex-
periment was carried out with 1 h of incubation with similar results.
100% activity equals 3148 pmol PEA/h/mg protein. Numbers indi-
cate the molar ratio except for oleate.
Fig. 4. E¡ect of di¡erent concentrations of alcohols on NAPE-PLD
activity. 100 WM of the substrate 1-palmitoyl-2-[1P-14C]linoleoyl-sn-
glycero-3-phospho(N-oleoyl)ethanolamine was incubated for 3 h (mi-
crosomes) or 1 h (PLD from St. sp.) under the described conditions,
various concentrations of alcohols added before sonication and pro-
tein from rat brain microsomes or 2 units of PLD from St. sp.
PhosphoImaging of the TLC plates identi¢ed the reaction products.
The same lack of transphosphatidylation was seen in ¢ve other ex-
periments.
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ity from microsomes isolated from elicitor-treated tobacco
(Nicotiana tabacum L.) cells [39]. In similar experiments using
rat brain microsomes and 0.5^100 WM mastoparan from Ves-
pula no stimulation was seen (data not shown).
3.5. Transphosphatidylation activity of NAPE-PLD
PLD from higher plants was ¢rst shown to catalyse a phos-
phatidyl transfer reaction in which a primary alcohol acts as
nucleophilic acceptor in place of water [40,41]. Later this
transphosphatidylation reaction was also recognised in rat
brain synaptosomes, catalysed by an oleate-dependent PLD
[31]. Mammalian PLD1 and PLD2 are also capable of cata-
lysing this reaction [2,3]. Today the transphosphatidylation
reaction is generally used to identify activation of PLD in
cell cultures and tissues.
The ability of alcohols to serve as substrates for an NAPE-
PLD-catalysed transphosphatidylation reaction is shown in
Fig. 4. NAPE-PLD from rat brain and rat heart microsomes
is not capable of catalysing a transphosphatidylation reaction
using either 1-butanol, ethanol, 1-propanol or 2-propanol as
substrates (Fig. 4 and data not shown). A positive control of
the reaction is shown using PLD from Streptomyces species.
Since most classes of PLDs are able to catalyse a trans-
phosphatidylation reaction the lack of this ability is seen as
a distinct feature of mammalian NAPE-PLD. So far only one
PLD activity, in yeast, has been described not to be capable of
catalysing a transphosphatidylation reaction. Therefore this
Ca2-dependent PLD with preference for hydrolysing PE
and PS over PC was suggested to be part of a new PLD
gene family [42,43]. The ¢ndings reported here open the pos-
sibility that mammalian NAPE-PLD may be part of this new
gene family.
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